At 12 weeks , 53.0 % of the combination therapy group achieved prolonged smoking abstinence and 56.2 % achieved 7-day point-prevalence smoking abstinence compared with 43.2 % and 48.6 % in varenicline monotherapy ( odds ratio [ OR ] , 1.49 ; 95 % CI , 1.05-2 .12 ; P = .03 and OR , 1.36 ; 95 % CI , 0.95-1 .93 ; P = .09 , respectively ) .